Get started
Author

Sigurd D. Süßmuth

Observed names: S D Süssmuth, S Süssmuth, S. D. Süssmuth, S. D. Süßmuth, S. D. Süssmuth, S. Sussmuth, S. Süßmuth, S. Süssmuth, S.D Süssmuth, S.D. Süssmuth, S.D. Süßmuth, Sigurd D Süssmuth, Sigurd D. Süßmuth, Sigurd D. Süssmuth, Sigurd D. Süssmuth,, Sigurd Dietrich Süßmuth, Sigurd Sussmuth, Sigurd Süssmuth, Sigurd Süßmuth, Siɡurd D. Süssmuth, Süssmuth, Sigurd D., Süßmuth, Sigurd
Observed institutions: Boehringer Ingelheim (Germany), University of Freiburg, Universität Ulm, Hertie Foundation, University and Rehabilitation Clinics Ulm, University Hospital Ulm, European Huntington's Disease Network, UCL Queen Square Institute of Neurology, University College London, University of Göttingen
ORCID: 0009-0008-9648-3831
Observed ORCID: 0009-0008-9648-3831
OpenAlex ID: A5113578739
Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study
2017 · Davina J Hensman Moss, Antonio F Pardiñas, et al. · The Lancet Neurology · 319
PDF
Axonal damage markers in cerebrospinal fluid are increased in ALS
2006 · J. Brettschneider, A. Petzold, et al. · Neurology · 268
Aggregation Substance Promotes Adherence, Phagocytosis, and Intracellular Survival ofEnterococcus faecaliswithin Human Macrophages and Suppresses Respiratory Burst
2000 · Sigurd D. Süßmuth, Albrecht Muscholl-Silberhorn, et al. · Infection and Immunity · 199
PDF
An exploratory double‐blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with H untington's disease
2014 · Sigurd D. Süssmuth, Salman Haider, et al. · British Journal of Clinical Pharmacology · 186
PDF
Tau protein in cerebrospinal fluid (CSF): a blood–CSF barrier related evaluation in patients with various neurological diseases
2001 · Sigurd D. Süssmuth, Hansotto Reiber, et al. · Neuroscience Letters · 103
Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum
2003 · Sigurd D Süssmuth, Hayrettin Tumani, et al. · Neuroscience Letters · 97
Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS
2012 · Markus Otto, Robert Bowser, et al. · Amyotrophic Lateral Sclerosis · 93
PDF
Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases
2008 · Hayrettin Tumani, Charlotte Teunissen, et al. · Expert Review of Molecular Diagnostics · 86
Cerebrospinal fluid biomarkers in Guillain-Barré syndrome – Where do we stand?
2009 · Johannes Brettschneider, Axel Petzold, et al. · Journal of Neurology · 82
A randomized, placebo‐controlled trial of AFQ056 for the treatment of chorea in Huntington's disease
2015 · Ralf Reilmann, Marie‐Laure Rouzade‐Dominguez, et al. · Movement Disorders · 81
Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases
2010 · Sarah Jesse, Johannes Brettschneider, et al. · Journal of Neurology · 80
PDF
CSF glial markers correlate with survival in amyotrophic lateral sclerosis
2010 · S. D. Süssmuth, A. D. Sperfeld, et al. · Neurology · 77
The association between plasma tryptophan catabolites and depression: The role of symptom profiles and inflammation
2021 · Yuri Milaneschi, Kelly A. Allers, et al. · Brain Behavior and Immunity · 74
PDF
Neurofilament heavy‐chain NfHSMI35 in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes
2006 · Johannes Brettschneider, Axel Petzold, et al. · Movement Disorders · 71
Comparison of smooth pursuit eye movement deficits in multiple system atrophy and Parkinson’s disease
2009 · Elmar H. Pinkhardt, Jan Kassubek, et al. · Journal of Neurology · 67
Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis
2005 · J Brettschneider, M Maier, et al. · Multiple Sclerosis Journal · 65
A randomized exploratory phase 2 study in patients with chemotherapy-related peripheral neuropathy evaluating whole-body vibration training as adjunct to an integrated program including massage, passive mobilization and physical exercises
2017 · Stefan S. Schönsteiner, Heidi Bauder Mißbach, et al. · Experimental Hematology and Oncology · 62
PDF
Biochemical Markers in CSF of ALS Patients
2008 · Sigurd Sussmuth, Johannes Brettschneider, et al. · Current Medicinal Chemistry · 59
Bupropion for the treatment of apathy in Huntington’s disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial
2017 · Harald Gelderblom, Torsten Wüstenberg, et al. · PLoS ONE · 57
PDF
Clinical manifestations of intermediate allele carriers in Huntington disease
2016 · Esther Cubo, María A. Ramos-Arroyo, et al. · Neurology · 56
The neuroanatomy of subthreshold depressive symptoms in Huntington's disease: a combined diffusion tensor imaging (DTI) and voxel-based morphometry (VBM) study
2013 · R. Sprengelmeyer, M. Orth, et al. · Psychological Medicine · 54
Abnormal resting-state connectivity of motor and cognitive networks in early manifest Huntington's disease
2014 · R. C. Wolf, F. Sambataro, et al. · Psychological Medicine · 53
Proteome Analysis of Cerebrospinal Fluid in Amyotrophic Lateral Sclerosis (ALS)
2008 · Johannes Brettschneider, Helga Mogel, et al. · Neurochemical Research · 53
Visual system integrity and cognition in early Huntington's disease
2014 · Robert C. Wolf, Fabio Sambataro, et al. · European Journal of Neuroscience · 47
PDF
Differential pattern of brain‐specific CSF proteins tau and amyloid‐beta in Parkinsonian syndromes
2010 · Sigurd D. Süssmuth, Ingo Uttner, et al. · Movement Disorders · 47
Works count: 93
Citation count: 3,073
H-index: 32
I10-index: 49
Year
Topic
Type